Allopurinol (allopurinol) tablets 300 mg. №30

active ingredient : allopurinol;

1 tablet contains allopurinol 300 mg;

excipients: powdered cellulose, microcrystalline cellulose, povidone, polyethylene glycol, crospovidone, talc,
anhydrous colloidal silicon dioxide, magnesium stearate.

Drugs that inhibit the formation of uric acid. ATX code M04A A01.

Allopurinol and its main metabolite oxypurinol disrupt the synthesis of uric acid, have urostatic properties, which are based mainly on the ability to suppress the enzyme xanthine oxidase, which catalyzes the oxidation of hypoxanthine to xanthine and xanthine to uric acid, which leads to a decrease in the concentration of uric acid and promotes the dissolution of urates.

Adults. Treatment of all forms of hyperuricemia not controlled by diet, with serum uric acid levels in the range of 535 µmol/l (9 mg/100 ml) and above; diseases caused by an increase in the level of uric acid in the blood serum, in particular gout, urate nephropathy and urate urolithiasis; secondary hyperuricemia of various origins; primary and secondary hyperuricemia in various hemoblastoses (acute leukemia, chronic myeloid leukemia, lymphosarcoma).

300 mg tablets

Children and adolescents weighing ≥ 45 kg:

• secondary hyperuricemia of various origins;
• urate nephropathy resulting from the treatment of leukemia;
• congenital enzyme deficiency, in particular Lesch-Nyhan syndrome (partial or complete deficiency of hypoxanthine-guanine phosphoribosyltransferase) and adenine phosphoribosyltransferase deficiency.

Hypersensitivity to allopurinol or any of the components of the drug. Severe renal dysfunction (creatinine clearance less than 2 ml / min) and liver. With a creatinine clearance of less than 20 ml / min, 300 mg tablets are not used.

adults

The daily dose is determined individually depending on the level of uric acid in the blood serum. To reduce the risk of adverse reactions, treatment should begin with allopurinol 100 mg once a day and increase the dosage only if the level of uric acid in the blood serum does not decrease sufficiently.

The following dosage regimens are recommended:

in mild conditions – from 100 to 200 mg per day;

in moderately severe conditions – from 300 to 600 mg per day;

in severe conditions – from 700 to 900 mg per day.

If the daily dose of allopurinol exceeds 300 mg, it should be divided into several doses (not more than 300 mg once).

When calculating the dose of the drug per patient’s body weight, doses of 2-10 mg/kg of body weight per day should be used.

Children and adolescents weighing ≥ 15 kg.

The daily dose of allopurinol is 10 mg/kg of body weight, divided into 3 doses.

The maximum daily dose is 400 mg. Use tablets of 100 mg.

Children and adolescents weighing ≥ 45 kg

The daily dose of allopurinol is 10 mg/kg of body weight, divided into 3 doses.

The maximum daily dose is 400 mg.

Elderly patients

Due to the lack of specific data on the use of allopurinol in this category of patients, it is recommended to take the lowest therapeutically reasonable doses. Consideration should be given to the possibility of impaired renal function in elderly patients.

Patients with renal insufficiency

Since allopurinol and its metabolites are excreted by the kidneys, if their function is impaired, an overdose is possible if the dose is not properly selected.

In severe renal impairment, the maximum daily dose is 100 mg. It is possible to use a single dose of 100 mg with an interval of more than a day (every 2-3 days).
If it is necessary to increase the dose, it is necessary to control the serum level of oxypurinol, which should not exceed 15.2 μg / ml.

In hemodialysis, after each session (2-3 times a week) apply 300-400 mg of allopurinol.

Patients with impaired liver function

Patients with impaired liver function should be given lower doses. At the beginning of treatment, it is recommended to periodically monitor the indicators of liver function tests. 300 mg tablets should not be given to these patients due to their high active ingredient content.

Tablets should be taken after meals, without chewing, along with plenty of liquid.
The duration of treatment depends on the course of the underlying disease. In order to prevent the formation of oxalate and urate stones and in primary hyperuricemia and gout, long-term therapy is necessary in most cases. For secondary hyperuricemia, short-term treatment is recommended according to the duration of the increase in uric acid levels.